
00380930552240 (باللغة العربية) |
00380930552240 (باللغة العربية) |
Table 1. The peripheral blood counts in patients with oncological and hematological disturbances after fetal stem cell transplantation
Table 2. Contents of leukocytes in peripheral blood after chemotherapy in hematological patients after fetal stem cells transplantation and in a control group
Table 3. Recovery of total leukocytes and neutrophyls in hematological patients with severe postchemotherapy neutropenia after fetal stem cells transplantation
Table 4. Peripheral blood indices in patients with cervical cancer after cell therapy (n=23)
Table 5. Immune indices in patients with cervical cancer after fetal stem cells transplantation
Table 6. Psychophysiological changes in cancer patients after the fetal stem cell transplantation
Table 1. The peripheral blood counts in patients with oncological and hematological disturbances after fetal stem cell treatment (n=26)
Term of observation | Erythrocytes 1012/l M ± m |
Hemoglobin g/l M ± m |
Thrombocytes 109/l M ± m |
Leukocytes 109/l M ± m |
Before treatment
|
2.65 ± 0.15 | 78.19 ± 4.25 | 79.40 ± 16.42 | 1.37 ± 0.16 |
After FSCT (days)
|
||||
3 | 2.72 ± 0.13 | 79.39 ± 3.91 | 133.20 ± 38.39 | 1.90 ± 0.31 |
5 | 2.75 ± 0.13 | 82.42 ± 3.51 | 191.92 ± 55.92 | 3.12 ± 1.05 |
7 | 2.87 ± 0.13 | 84.77 ± 3.52 | 153.34 ± 37.35 | 4.46 ± 1.78 |
11 | 3.12 ± 0.15 | 91.27 ± 3.54 | 164.23 ± 29.54 | 4.21 ± 0.69 |
13 | 3.40 ± 0.16 | 96.19 ± 3.50 | 212.65 ± 37.95 | 4.68 ± 0.89 |
30 | 3.51 ± 0.16 | 103.27 ± 3.67 | 163.73 ± 20.00 | 5.20 ± 1.01 |
Table 2. Contents of leukocytes in peripheral blood after chemotherapy in hematological patients after fetal stem cells treatment (n=26) and in a control group (n=30)
Days after Treatment |
After Fetal Stem Cells Treatment (n=26) |
Control group (n=30) |
||||
|
M | m | % | M | m | % |
0 | 1.37 | 0.16 | 100 | 1.20 | 0.07 | 100 |
3 | 1.90 | 0.31 | 138 | 1.17 | 0.09 | 97.5 |
5 | 3.12 | 1.05 | 228 | — | — | — |
7 | 4.46 | 1.78 | 325 | 1.18 | 0.11 | 97.7 |
11 | 4.21 | 0.69 | 307 | 1.51 | 0.15 | 126 |
13 | 4.68 | 0.89 | 341 | 2.10 | 0.20 | 175 |
30 | 5.20 | 1.01 | 379 | 4.10 | 0.48 | 341 |
Table 3. Recovery of total leukocytes and neutrophyls in hematological patients with severe postchemotherapy neutropenia after fetal stem cells treatment (n=16)
Days after treatment | Total leukocytes | Neutrophils | ||||
|
M | m | % | M | m | % |
0 | 0.98 | 0.17 | 100 | 0.18 | 0.07 | 100 |
3 | 1.24 | 0.14 | 126 | 0.40 | 0.12 | 222 |
5 | 3.02 | 1.56 | 308 | 1.76 | 1.24 | 977 |
7 | 4.79 | 2.89 | 488 | 2.18 | 1,627 | |
11 | 3.59 | 0.91 | 366 | 1.79 | 0.76 | 994 |
13 | 3.78 | 1.17 | 385 | 2.06 | 0.95 | 1,144 |
30 | 4.83 | 1.50 | 492 | 1.95 | 0.54 | 1,083 |
Table 4. Peripheral blood indices in patients with cervical cancer after cell therapy (n=23)
Blood indices | St.in | Before stem cell therapy |
Days after cell therapy | ||||
3 | 7 | 11 | 15 | 30 | |||
Erythrocytes, 1012/l |
M m p |
3.60 0.11 |
3.54 0.19 |
3.59 0.16 |
3.62 0.17 |
4.05 0.21 |
3.89 0.19 |
Hemoglobin, G/l |
M m p |
111.4 6.0 |
106.3 5.25 |
109.9 5.08 |
111.5 4.79 |
115.8 4.53 |
120.7 4.33 |
Leukocytes, 109/l |
M m p |
2.66 0.29 |
3.14 0.53 |
3.83 0.49 <0.05 |
3.53 0.52 |
3.36 0.28 <0.05 |
3.55 0.24 <0.01 |
Neutroph. stab, % |
M m p |
6.29 1.38 |
5.14 1.03 |
4.93 0.55 |
5.50 1.29 |
5.79 1.35 |
5.38 1.02 |
Neutroph. stab, G/l |
M m p |
180.9 34.1 |
154.6 41.6 |
190.7 30.3 |
269.0 115.3 |
198.4 46.3 |
199.8 44.8 |
Neutroph. segmented, % |
M m p |
54.3 2.56 |
58.6 2.73 |
58.7 2.38 |
64.1 2.57 <0.01 |
63.1 1.90 <0.005 |
64.7 2.54 <0.005 |
Neutrophils segm., 109/l |
M m p |
1.48 0.20 |
1.84 0.31 |
2.29 0.33 <0.05 |
2.24 2.98 <0.05 |
2.04 0.16 <0.05 |
2.18 0.08 <0.05 |
Lymphocytes, % |
M m p |
20.6 2.06 |
20.9 2.31 |
23.1 1.80 |
17.2 1.62 |
18.6 1.95 |
15.7 1.93 |
Lymphocytes, 109/l |
M m p |
0.55 0.07 |
0.75 0.22 |
0.89 0.18 |
0.59 0.09 |
0.63 0.10 |
0.48 0.06 |
Monocytes, % |
M m p |
8.21 0.86 |
9.29 1.15 |
9.64 1.04 |
8.50 1.47 |
7.14 1.03 |
8.23 1.27 |
Monocytes, 109/l |
M m p |
0.21 0.02 |
0.27 0.04 |
0.34 0.04 0.05 |
0.32 0.08 |
0.23 0.03 |
0.27 0.05 |
Table 5. Immune indices in patients with cervical cancer after fetal stem cells treatment
Immunological tests | Before FSCT |
Two weeks after FSCT |
After radiotherapy |
|||
n=7 | n=7 | n=7 | ||||
M | m | M | m | M | m | |
Leukocytes, 109/l | 2.90 | 0.14 | 3.91 | 0.38 | 3.54 | 0.40 |
Lymphocytes, % | 16.00 | 4.62 | 16.71 | 2.13 | 20.14 | 3.84 |
B-lymphocytes, (CD19+), % | 13.96 | 1.64 | 10.21 | 1.33 | 11.00 | 0.63 |
B-lymphocytes, per mm3 | 66.34 | 23.74 | 68.02 | 15.5 | 70.76 | 8.75 |
T-lymphocytes, (CD3+), % | 38.42 | 7.87 | 39.71 | 5.13 | 50.71 | 3.97 |
T-lymphocytes, per mm3 | 168.98 | 67.03 | 254.90 | 58.9 | 332.62 | 54.16 |
T-helpers (CD4+), % | 25.46 | 5.76 | 27.14 | 3.62 | 33.59 | 2.40 |
T-helpers, mm3 | 112.11 | 47.36 | 177.90 | 44.9 | 220.12 | 34.76 |
T-suppressers (CD8+), % | 12.31 | 2.66 | 15.08 | 1.56 | 18.86 | 2.01 |
T-suppressers, mm3 | 59.85 | 26.95 | 95.65 | 17.9 | 121.17 | 18.50 |
NK-cells (CD16+), % | 17.30 | 2.63 | 21.94 | 6.04 | 15.56 | 1.90 |
NK-cells (CD16+), per mm3 | 84.55 | 32.98 | 129.87 | 34.3 | 95.01 | 8.79 |
CD4+/CD8+ | 2.03 | 0.36 | 1.70 | 0.11 | 1.77 | 0.09 |
Table 6. Psychophysiological changes in cancer patients after the fetal stem cell treatment
75 clinical cases were analyzed: with cytostatic disease (50), without signs of cytostatic disease (25). Assessment of disorders of psychic condition, depressive symptoms, emotional changes, spirits, and changes of thinking, memory and intellect were carried out.
Before FSCT |
First 6–12 hours | 1–3 days |
5–10 days |
3–6 weeks |
3–6 months |
|
State of spirit | ||||||
Depression | +++ | – | – | – | – | + |
Composure, optimism | – | + | + | + | ++ | ++ |
Desperation | +++ | – | – | – | + | + |
Tranquillity, hope | – | – | + | + | ++ | ++ |
Emotional sphere | ||||||
Self awareness | – | + | ++ | + | ++ | ++ |
Activity | – | ++ | + | ++ | ++ | ++ |
Anxiety | ++ | + | + | – | – | + |
Stability of emotional state | – | + | + | ++ | ++ | ++ |
Mental capacity | ||||||
Attention (strength and stability of concentration), | + | ++ | +++ | + | ++ | ++ |
Improvement of thinking process, memory, creativity, decreasing of manifestations of senile dementia | + | + | ++ | ++ | +++ | +++ |
Improvement of contact with doctors and people around | + | ++ | ++ | ++ | ++ | ++ |
Improvement of quality of sleeping | – | + | ++ | ++ | ++ | + |
Sexual energy | – | – | + | ++ | + | + |